Micropos Medical
Enabling accuracy in prostate cancer care
Micropos Medical is a Swedish medical device company that develops, manufactures, and sells technology enabling enhanced radiotherapy cancer treatment. Its product Raypilot® System, generates high precision as well as high efficiency through real-time tumour tracking in radiation treatment of prostate cancer. Raypilot is marketed in Europe and the US.
The Micropos Medical share is traded under the stock ticker MPOS on the Spotlight Stock Market.
For more information about the share, please visit Spotlight
Interim Reports
annual reports
Financial calendar
| DATE | EVENTS |
|---|---|
| 30 January 2026 | Interim report Q4/Year-end Report 2025 |
| 30 April 2026 | Interim report Q1 2026 |
| 31 July 2026 | Interim report Q2 2026 |
| 30 October 2026 | Interim report Q3 2025 |
| 29 January 2027 | Interim report Q4 2026 |
For additional information, please contact:
Richard Forsberg, CEO, Micropos Medical AB (publ)
+46-31-760 80 05, info@micropos.se
-
news
Strong engagement as Movember kicked off at Hotel Riverton
With an almost full house on Monday evening, around 60 curious participants gathered to learn about the latest developments in radiation therapy and advances in the treatment of prostate cancer. […]
COMPANY INFO
LEARN MORE ABOUT OUR TEAM, BOARD AND OUR PRODUCTS
NEWSLETTER
Follow us on LinkedIn
Let’s keep in touch